A former molecular geneticist at Oak Ridge National Laboratory will discuss regenerative medicine and a potential treatment for severe COVID-19 disease patients and those who struggle with “long haul” symptoms.
The talk by Cymbeline “Bem” Culiatâ€”co-founder, president, and chief science officer of NellOne Therapeutics in Knoxvilleâ€”will speak virtually to Friends of ORNL at noon Tuesday, February 8.
“While at ORNL, Culiat discovered the role of the NELL1 signaling protein in fostering the growth and maturation of musculoskeletal and cardiovascular tissues in mice and other mammals, including humans,” a press release said. “Her biotech company focuses on using her discovery to advance regenerative medicine, which involves replacing, engineering, or regenerating human or animal cells, tissues, or organs to promote healing and restore normal function. In contrast, traditional medicine typically provides treatment of symptoms rather than addressing root causes.”
To view the virtual lecture, click on the talk title on the homepage of the www.fornl.org website and click on the Zoom link near the top of the page describing the lecture. Here is Culiatâ€™s summary of what she will talk about:
â€œThe global community is addressing the third year of a constantly changing deadly pandemic that has now claimed at least 5.7 million lives (~883,000 in the United States), overwhelmed the healthcare system, strained government resources and economies, disrupted communities, and devastated families. Despite the availability of several vaccines, antivirals, and therapeutics, an increasing concern is that the lung and heart tissue damage resulting from infection with the COVID-19 virus is a major cause of death or severe disability in survivors.
â€œNellOne Therapeutics, Inc. (NellOne) is pioneering advances in regenerative medicine that can restore injured tissue to its normal functional state. The NELL1 signaling proteinâ€™s healing properties stem from its activity during early mammalian development when an extracellular matrix is produced. This pro-healing environment promotes pathways that regulate inflammation, increase tissue survival under low-oxygen or other adverse conditions, recruit stem cells, and enhance blood vessel formation.
â€œThese processes kick-start and sustain the formation and maturation of new tissue that can replace damaged tissues. The biology and tissue-healing properties of the NELL1 protein have been demonstrated in major organ systems, such as bone, cartilage, skin, skeletal muscle, as well as heart muscle and the lungs.
â€œIn 2020, NellOne pivoted and began developing NV1, its proprietary variant of the naturally occurring NELL1, as a recombinant protein drug for healing lung tissue damaged by COVID-19 and other viral infections. Based on promising data from mouse and cultured human lung tissue studies, NellOne is pursuing a fast-track path toward obtaining ultimate approval of the new drug through the FDAâ€™s Coronavirus Treatment Acceleration Program.
â€œSupported by federal, state, and private funding, NellOne Therapeutics is working to meet the milestones for demonstrating the new drugâ€™s efficacy and safety. Our goal is an IND filing (Introduction of a New Drug) of our recombinant protein drug as a ‘first-in-class’ therapeutic for clinical tests on patients suffering from severe viral infections.â€
A native of the Philippines who lives in Oak Ridge, Culiat is a biologist, inventor, entrepreneur, author, and educator. Her inventions are protected by 24 NELL1 patents (20 UT-Battelle and four NellOne-owned), of which 22 have been issued in eight countries, the press release said. She co-authored the book â€œDesigned to Heal: What the Body Shows Us about Healing Wounds, Repairing Relationships, and Restoring Communityâ€ (McLaurin and Culiat 2021, Tyndale Momentum), which is available through Amazon.com.
In 2008, Culiat co-founded NellOne Therapeutics Inc., which has been developing human and veterinary drugs and devices, as well as therapies for lung and heart tissue damage induced by viral infections such as COVID-19 and influenza. She has won many awards in both the U.S. and Philippines, including the Federal Laboratory Consortium Excellence in Technology Transfer award in 2008 and the Department of Science and Technology Outstanding Filipina Scientist in 2015.
In the 1980s, she earned a bachelor’s degree in cell biology and a master’s degree in genetics from the University of the Philippines in Laguna, where she taught genetics, cell biology, and molecular biology. In 1994, she received a doctorate in biomedical sciences from the University of Tennessee in Knoxville and, as a recipient of the prestigious Alexander Hollaender Distinguished Postdoctoral Fellowship, she completed postdoctoral training in molecular genetics and genomics at ORNL (1995-1999), the press release said.
She was adjunct faculty of the UTK Graduate School of Genome Sciences and Technology (1999-2009). Long a mentor of science students and young scientists, she received in 2006 the Outstanding Mentor Award from the Department of Energy Office of Science. Currently, she is a guest lecturer at private and public universities and supports STEM education in public schools.
This press release and photo were submitted by Carolyn Krause.
More information will be added as it becomes available.
Most news stories on Oak Ridge Today are free, brought to you by Oak Ridge Today with help from our advertisers, contributors, and subscribers. This is a free story. Thank you to our advertisers, contributors, and subscribers. You can see what we cover here.
Do you appreciate this story or our work in general? If so, please consider a monthly subscription to Oak Ridge Today. See our Subscribe page here. Thank you for reading Oak Ridge Today!
Alternatively, you can donate to support our work here. Thank you for your support!
Copyright 2021 Oak Ridge Today.Â All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.